Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer
Abstract Programmed Death Ligand 1 (PD-L1) is crucial in regulating the immunological tolerance in non-small cell lung cancer (NSCLC). Alveolar macrophage (AM)-derived PD-L1 binds to its receptor, PD-1, on surveilling lymphocytes, leading to lymphocyte exhaustion. Increased PD-L1 expression is assoc...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-12-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-26650-9 |
| _version_ | 1797973696820805632 |
|---|---|
| author | F. Polverino D. Mirra C. X. Yang R. Esposito G. Spaziano J. Rojas-Quintero M. Sgambato E. Piegari A. Cozzolino E. Cione L. Gallelli A. Capuozzo C. Santoriello L. Berrino J. P. de- Torres T. L. Hackett M. Polverino B. D’Agostino |
| author_facet | F. Polverino D. Mirra C. X. Yang R. Esposito G. Spaziano J. Rojas-Quintero M. Sgambato E. Piegari A. Cozzolino E. Cione L. Gallelli A. Capuozzo C. Santoriello L. Berrino J. P. de- Torres T. L. Hackett M. Polverino B. D’Agostino |
| author_sort | F. Polverino |
| collection | DOAJ |
| description | Abstract Programmed Death Ligand 1 (PD-L1) is crucial in regulating the immunological tolerance in non-small cell lung cancer (NSCLC). Alveolar macrophage (AM)-derived PD-L1 binds to its receptor, PD-1, on surveilling lymphocytes, leading to lymphocyte exhaustion. Increased PD-L1 expression is associated with cigarette smoke (CS)-exposure. However, the PD-L1 role in CS-associated lung diseases associated with NSCLC, such as chronic obstructive pulmonary disease (COPD), is still unclear. In two different cohorts of ever smokers with COPD or NSCLC, and ever and never smoker controls, we evaluated PD-L1 expression: (1) via cutting-edge digital spatial proteomic and transcriptomic profiling (Geomx) of formalin-fixed paraffin-embedded (FFPE) lung tissue sections (n = 19); and (2) via triple immunofluorescence staining of bronchoalveolar lavage (BAL) AMs (n = 83). PD-L1 mRNA expression was also quantified in BAL AMs exposed to CS extract. PD-L1 expression was increased in the bronchiolar wall, parenchyma, and vascular wall from mild-moderate (GOLD 1–2) COPD patients compared to severe-very severe (GOLD 3–4) COPD patients and controls. Within all the COPD patients, PD-L1 protein expression was associated with upregulation of genes involved in tumor progression and downregulation of oncosuppressive genes, and strongly directly correlated with the FEV1% predicted, indicating higher PD-L1 expression in the milder vs. more severe COPD stages. In bronchioles, PD-L1 levels were strongly directly correlated with the number of functionally active AMs. In BAL, we confirmed that AMs from patients with both GOLD 1–2 COPD and NSCLC had the highest and similar, PD-L1 expression levels versus all the other groups, independently from active cigarette smoking. Intriguingly, AMs from patients with more severe COPD had reduced AM PD-L1 expression compared to patients with mild COPD. Acute CS extract stimulation increased PD-L1 mRNA expression only in never-and not in ever-smoker AMs. Lungs from patients with mild COPD and NSCLC are characterized by a similar strong PD-L1 expression signature in bronchioles and functionally active AMs compared to patients with severe COPD and controls. Active smoking does not affect PD-L1 levels. These observations represent a new resource in understanding the innate immune mechanisms underlying the link between COPD and lung cancer onset and progression and pave the way to future studies focused on the mechanisms by which CS promotes tumorigenesis and COPD. |
| first_indexed | 2024-04-11T04:07:20Z |
| format | Article |
| id | doaj.art-5a2c1e1c78fe402a86e9bffd1f2d0752 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-11T04:07:20Z |
| publishDate | 2022-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-5a2c1e1c78fe402a86e9bffd1f2d07522023-01-01T12:16:50ZengNature PortfolioScientific Reports2045-23222022-12-0112111610.1038/s41598-022-26650-9Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancerF. Polverino0D. Mirra1C. X. Yang2R. Esposito3G. Spaziano4J. Rojas-Quintero5M. Sgambato6E. Piegari7A. Cozzolino8E. Cione9L. Gallelli10A. Capuozzo11C. Santoriello12L. Berrino13J. P. de- Torres14T. L. Hackett15M. Polverino16B. D’Agostino17Pulmonary and Critical Care Medicine, Department of Medicine, Baylor College of MedicineUniversity of Campania “Luigi Vanvitelli”University of British ColumbiaUniversity of Campania “Luigi Vanvitelli”University of Campania “Luigi Vanvitelli”Pulmonary and Critical Care Medicine, Department of Medicine, Baylor College of MedicineUniversity of Campania “Luigi Vanvitelli”University of Campania “Luigi Vanvitelli”University of Campania “Luigi Vanvitelli”University of CalabriaUniversity of CatanzaroOspedale “M. Scarlato”Ospedale Antonio CardarelliUniversity of Campania “Luigi Vanvitelli”Queen’s UniversityUniversity of British ColumbiaOspedale “M. Scarlato”University of Campania “Luigi Vanvitelli”Abstract Programmed Death Ligand 1 (PD-L1) is crucial in regulating the immunological tolerance in non-small cell lung cancer (NSCLC). Alveolar macrophage (AM)-derived PD-L1 binds to its receptor, PD-1, on surveilling lymphocytes, leading to lymphocyte exhaustion. Increased PD-L1 expression is associated with cigarette smoke (CS)-exposure. However, the PD-L1 role in CS-associated lung diseases associated with NSCLC, such as chronic obstructive pulmonary disease (COPD), is still unclear. In two different cohorts of ever smokers with COPD or NSCLC, and ever and never smoker controls, we evaluated PD-L1 expression: (1) via cutting-edge digital spatial proteomic and transcriptomic profiling (Geomx) of formalin-fixed paraffin-embedded (FFPE) lung tissue sections (n = 19); and (2) via triple immunofluorescence staining of bronchoalveolar lavage (BAL) AMs (n = 83). PD-L1 mRNA expression was also quantified in BAL AMs exposed to CS extract. PD-L1 expression was increased in the bronchiolar wall, parenchyma, and vascular wall from mild-moderate (GOLD 1–2) COPD patients compared to severe-very severe (GOLD 3–4) COPD patients and controls. Within all the COPD patients, PD-L1 protein expression was associated with upregulation of genes involved in tumor progression and downregulation of oncosuppressive genes, and strongly directly correlated with the FEV1% predicted, indicating higher PD-L1 expression in the milder vs. more severe COPD stages. In bronchioles, PD-L1 levels were strongly directly correlated with the number of functionally active AMs. In BAL, we confirmed that AMs from patients with both GOLD 1–2 COPD and NSCLC had the highest and similar, PD-L1 expression levels versus all the other groups, independently from active cigarette smoking. Intriguingly, AMs from patients with more severe COPD had reduced AM PD-L1 expression compared to patients with mild COPD. Acute CS extract stimulation increased PD-L1 mRNA expression only in never-and not in ever-smoker AMs. Lungs from patients with mild COPD and NSCLC are characterized by a similar strong PD-L1 expression signature in bronchioles and functionally active AMs compared to patients with severe COPD and controls. Active smoking does not affect PD-L1 levels. These observations represent a new resource in understanding the innate immune mechanisms underlying the link between COPD and lung cancer onset and progression and pave the way to future studies focused on the mechanisms by which CS promotes tumorigenesis and COPD.https://doi.org/10.1038/s41598-022-26650-9 |
| spellingShingle | F. Polverino D. Mirra C. X. Yang R. Esposito G. Spaziano J. Rojas-Quintero M. Sgambato E. Piegari A. Cozzolino E. Cione L. Gallelli A. Capuozzo C. Santoriello L. Berrino J. P. de- Torres T. L. Hackett M. Polverino B. D’Agostino Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer Scientific Reports |
| title | Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer |
| title_full | Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer |
| title_fullStr | Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer |
| title_full_unstemmed | Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer |
| title_short | Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer |
| title_sort | similar programmed death ligand 1 pd l1 expression profile in patients with mild copd and lung cancer |
| url | https://doi.org/10.1038/s41598-022-26650-9 |
| work_keys_str_mv | AT fpolverino similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT dmirra similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT cxyang similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT resposito similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT gspaziano similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT jrojasquintero similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT msgambato similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT epiegari similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT acozzolino similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT ecione similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT lgallelli similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT acapuozzo similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT csantoriello similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT lberrino similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT jpdetorres similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT tlhackett similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT mpolverino similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer AT bdagostino similarprogrammeddeathligand1pdl1expressionprofileinpatientswithmildcopdandlungcancer |